Critical Limb Ischemia Market Analysis: Major Players, Lucrative Segments And Top Geographies
29 May, 2023
The global critical limb ischemia treatment market size is expected to grow from $3.11 billion in 2022 to $3.39 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global critical limb ischemia treatment market size is expected to reach $4.62 billion in 2027 at a CAGR of 8.0%.
Global Critical Limb Ischemia Market Key Driver
The increased prevalence of diabetes mellitus and peripheral artery disease is predicted to drive the critical limb ischemia therapy market forward. Diabetes mellitus is a metabolic disorder characterised by high blood glucose levels. Peripheral artery disease is a condition in which the arteries in the legs constrict, limiting blood flow to the arms or legs. Diabetes and peripheral artery disease raise the risk of vascular complications and amputation, making them risk factors for critical limb ischemia. As a result, the increased prevalence of diabetes mellitus and peripheral artery disease is propelling the critical limb ischemia market forward.
Get a sample of the global critical limb ischemia market reportGlobal Critical Limb Ischemia Market Segments
The global critical limb ischemia market is segmented:
1) By Type: Devices, Drugs, Surgery
2) By Medication: Antihypertensive Agents, Antiplatelet Drugs, Antithrombotic Agents, Other Medications
3) By Application: Hospital, Clinic, Other Applications
4) By Geography:The regions covered in the critical limb ischemia market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global critical limb ischemia market.
Major Critical Limb Ischemia Industry Players
Medtronic Plc, Boston Scientific Corporation, ThermoGenesis Holdings Inc., Abbott Laboratories, Pluri Biotech Ltd., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Cynata Therapeutics Ltd, Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Biotronik SE & Co KG, Teva Pharmaceutical Industries Ltd., Aldagen Inc.
Get the full global critical limb ischemia market report
Critical Limb Ischemia Market Overview
Critical limb ischemia treatment refers to re-establishing blood flow to the area affected with critical limb ischemia, a chronic condition where blood flow to one or two of the hands, and legs are severely blocked causing numbness and pain. Treatment includes diagnosis and treating patients by medication, surgery using devices, and others.
Critical Limb Ischemia Global Market Report 2023 provides data on the global critical limb ischemia market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The critical limb ischemia market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.